Should benefit–risk assessment have its own drug “label”?
R Scott BraithwaiteSection of Value and Comparative Effectiveness, Division of General Internal Medicine, New York University School of Medicine, New York, NY, USAAbstract: Many consumers and clinicians incorrectly believe that the Food and Drug Administration (FDA) approval of a new therapeutic imp...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-08-01
|
| Series: | Drug, Healthcare and Patient Safety |
| Online Access: | http://www.dovepress.com/should-benefitndashrisk-assessment-have-its-own-drug-ldquolabelrdquo-a8011 |